Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into 6 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Andrew Phillips began work on HIV in 1988 after working for five years on cardiovascular epidemiology. His work in the HIV field over the past 20 years, which has resulted in over 400 publications, has been largely based on design and analysis of cohorts of people with HIV. This began with work on describing the link between the CD4 count and risk of AIDS and other aspects of HIV natural history, such as the role of some immune activation markers. He then moved onto studies examining the effects of antiretroviral therapy, with a particular interest in virologic failure, drug resistance and clinical endpoints. Observational studies on which he has worked include the Royal Free Haemophilia Cohort, EuroSIDA, CASCADE, UK CHIC and D.A.D. Along with several European colleagues he has promoted collaboration between cohorts in order to maximise the statistical power available to study clinically important issues. Andrew Phillips also has an interest in design and analysis of randomized clinical trials, being involved in several trials, including SMART and START. Much of this work has been as part of a long standing collaboration with the Copenhagen HIV Programme. Lastly, he has developed and worked on theoretical models of HIV infection and the effects of ART which have been used to help to understand events in primary infection, how the rate of viral rebound after interruption of ART provides a measure of viral replicative capacity, and the consequences of different ART monitoring strategies for resistance and survival.
Professor Emery is Head of the Therapeutic and Vaccine Research Program at the National Centre in HIV Epidemiology and Clinical Research, affiliated with the Faculty of Medicine at the University of New South Wales in Sydney Australia (UNSW).
Professor Emery leads a team of researchers who design and conduct. The focus of his teams research at UNSW is the design, conduct and reporting of clinical trials in HIV medicine. The research objectives fall under three categories. Firstly, studies to examine the safety and efficacy of new treatments or treatment strategies. Secondly, studies to evaluate the safety and characteristics of candidate vaccines for treatment and prevention of HIV infection and thirdly, studies conducted on subsets of data or biological tissues derived from clinical trials with which to inform our understanding of pathogenesis and antiretroviral drug toxicities.